Page last updated: 2024-08-26

mafosfamide and Melanoma

mafosfamide has been researched along with Melanoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19904 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gambacorti-Passerini, C; Parmiani, G; Rivoltini, L; Supino, R1
Myers, DE; Vallera, DA1
Erba, E; Fossati, G; Gambacorti-Passerini, C; Parmiani, G; Radrizzani, M1
Hoon, DB; Jung, T; McBride, WH; Morton, DL; Naungayan, J; Nizze, A1

Reviews

1 review(s) available for mafosfamide and Melanoma

ArticleYear
Immunotoxins containing ricin.
    Cancer treatment and research, 1988, Volume: 37

    Topics: Ammonium Chloride; Antibodies, Monoclonal; Cross-Linking Reagents; Cyclophosphamide; Drug Evaluation; Drug Synergism; Galactose; Humans; Immunotoxins; Leukemia; Melanoma; Neoplasms; Receptors, Mitogen; Ricin; Yttrium

1988

Other Studies

3 other study(ies) available for mafosfamide and Melanoma

ArticleYear
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
    International journal of cancer, 1989, May-15, Volume: 43, Issue:5

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line; Cisplatin; Cyclophosphamide; Cytotoxicity, Immunologic; Doxorubicin; Drug Resistance; Humans; Killer Cells, Natural; Lymphocyte Activation; Lymphokines; Melanoma; Tumor Cells, Cultured

1989
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.
    Cancer research, 1987, May-15, Volume: 47, Issue:10

    Topics: Carcinoma, Small Cell; Cell Line; Clone Cells; Cyclophosphamide; Flow Cytometry; Fluorometry; Humans; Immunotherapy; In Vitro Techniques; Interleukin-2; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Melanoma

1987
Cyclophosphamide-induced alterations in human monocyte functions.
    Journal of leukocyte biology, 1987, Volume: 42, Issue:6

    Topics: Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Humans; Immunity, Cellular; Interleukin-1; Leukocytes, Mononuclear; Melanoma; Tumor Necrosis Factor-alpha; Vaccination

1987